Found: 20
Select item for more details and to access through your institution.
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 8, p. 1277, doi. 10.3390/jpm12081277
- By:
- Publication type:
- Article
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00040
- By:
- Publication type:
- Article
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 2, p. 587, doi. 10.1007/s10637-020-01018-w
- By:
- Publication type:
- Article
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1365, doi. 10.1007/s10637-020-00937-y
- By:
- Publication type:
- Article
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 581, doi. 10.1007/s10637-017-0556-7
- By:
- Publication type:
- Article
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835919897546
- By:
- Publication type:
- Article
Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference.
- Published in:
- Cancers, 2024, v. 16, n. 11, p. 1989, doi. 10.3390/cancers16111989
- By:
- Publication type:
- Article
Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6213, doi. 10.3390/cancers14246213
- By:
- Publication type:
- Article
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
- Published in:
- Cancers, 2019, v. 11, n. 4, p. 548, doi. 10.3390/cancers11040548
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758834017746040
- By:
- Publication type:
- Article
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 6, p. 1022, doi. 10.1038/s41416-023-02375-y
- By:
- Publication type:
- Article
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
- Published in:
- Journal of Translational Medicine, 2008, v. 6, p. 1, doi. 10.1186/1479-5876-6-53
- By:
- Publication type:
- Article
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
- Published in:
- PLoS ONE, 2023, v. 17, n. 3, p. 1, doi. 10.1371/journal.pone.0282512
- By:
- Publication type:
- Article
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00572-9
- By:
- Publication type:
- Article
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
- Published in:
- 2016
- By:
- Publication type:
- Letter
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
- Published in:
- BMC Cancer, 2008, v. 8, p. 1, doi. 10.1186/1471-2407-8-9
- By:
- Publication type:
- Article